Oticon Medical General Manager after US FDA approval: It's a competitive situation

Demant's bone-anchored division Oticon Medical will be put to the test when establishing itself on the US market for cochlear implants following the FDA approval last week. Competing companies are far ahead, and the Danish firm still has gaps to close in its product range, according to General Manager Jes Olsen.

On Thursday last week, Demant's bone-anchored division was delighted to announce that the US Food and Drug Administration (FDA) has given the necessary authorization for the Danish hearing company to sell and market its cochlear implant system Neuro 2 on what is unconditionally the largest market in the world.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Ambu credits MDR milestone to fastidiousness

All of Medtech firm Ambu’s products already live up to the new EU rules for medical devices, something the firm attributes to a good sense of how much effort living up to the new legislation would require.

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs